Cellular, Gene, and Cell-Based Gene Therapy
Customize your policy alerts
Sign up for CareSource Georgia Policy MP-AD-1623 alerts
Get alerted when Policy MP-AD-1623 changes without checking for updates manually.
Monitor payer policy activity
Administrative policy describing CareSource Georgia's stance and administrative rules for cellular, gene, and cell-based gene therapies, including applicability to Marketplace plans and requirements to refer to Evidence of Coverage for benefits and prior authorization requirements.
No material clinical or coverage changes in this revision.
Coverage Principles and Indications
Coverage principles
Administrative coverage principles — benefits and eligibility are determined by member-specific documents; services must be medically necessary and may require prior authorization.
Therapies and interventions aimed at genetic disorders, cancers, and certain infections where cellular or gene-based approaches are being used or studied.
Covered when services involve cellular or gene-based approaches for the following disease areas under investigation; this document lists investigational/target disease areas but does not define indication-specific coverage criteria — refer to the member's EOC/SOB and CareSource medical policies for eligibility and prior authorization requirements.
ONE of
- Disorders caused by a gene or protein deficiency for which gene therapy is being studied (examples include sickle cell disease, hemophilia, Duchenne muscular dystrophy).
- Cancers for which cellular or gene-based therapies (eg, CAR T-cell therapy, gene-modified immunotherapies) are being studied or used. Examples include certain lymphomas and multiple myeloma where FDA‑approved CAR‑T products exist.
- Inherited retinal disorders and other retinal dystrophies under investigation for gene therapy.
- Autoimmune or metabolic conditions under active investigation for gene-based interventions (examples noted include type 1 diabetes and idiopathic macular telangiectasia type 2).
- Certain infections where gene- or cell-based approaches are being studied as therapeutic strategies.
Coding and Authorization
| No codes listed |
Provider Requirements and Authorization
Prior Authorization and Medical Necessity
Services, procedures, and pharmaceuticals that are a covered benefit must be medically necessary and meet standards of good medical practice; they may also be subject to prior authorization. Refer to the member's Evidence of Coverage (EOC) and Schedule of Benefits (SOB) for coverage eligibility and plan-specific criteria.
- Medically necessary requirement
- Prior authorization may be required per member EOC/SOB
- If plan contract (EOC) conflicts with this policy, the plan contract controls
Definitions
Exclusions
This policy explicitly excludes stem cell transplants in which no genetic manipulation is performed on the donor cell. The administrative guidance in this document is not intended to apply to standard stem cell transplant procedures that do not involve gene modification.
Cellular therapies that do involve genetic modification (for example, engineered immunotherapies such as CAR T-cell products) remain within the scope of this policy and are addressed elsewhere; however, routine autologous or allogeneic stem cell transplants without genetic alteration are not covered by the provisions of this policy.
Policy Revision History
Policy became effective as an administrative policy for Cellular, Gene, and Cell-Based Gene Therapy (Policy MP-AD-1623).
New policy was approved by committee (document notes 'New policy, approved at Committee').
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.